These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16363425)

  • 21. Improvement of cardiovascular risk profile in an elderly population of low social level: the ICON (Improving Cardiovascular risk profile in Older Neapolitans) study.
    Marotta T; Viola S; Ferrara F; Ferrara LA
    J Hum Hypertens; 2007 Jan; 21(1):76-85. PubMed ID: 17096010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the prevention and treatment of cardiovascular disease.
    Weisfeldt ML; Zieman SJ
    Health Aff (Millwood); 2007; 26(1):25-37. PubMed ID: 17211011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Educational approach to patients with cardiovascular risk factors].
    Auer R; Morin D; Darioli R; Cornuz J; Rodondi N
    Rev Med Suisse; 2008 Mar; 4(148):657-60. PubMed ID: 18459661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular disease and global health: threat and opportunity.
    Greenberg H; Raymond SU; Leeder SR
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W-5-31-W-5-41. PubMed ID: 15671084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A practical approach to reducing cardiovascular risk factors.
    Fonarow GC
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S25-36. PubMed ID: 17934391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type-2 diabetes mellitus related cardiovascular risk: new options for interventions to reduce risk and treatment goals.
    Hobbs FD
    Atheroscler Suppl; 2006 Aug; 7(4):29-32. PubMed ID: 16822723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality indicators for the prevention and management of cardiovascular disease in primary care in nine European countries.
    Campbell SM; Ludt S; Van Lieshout J; Boffin N; Wensing M; Petek D; Grol R; Roland MO
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):509-15. PubMed ID: 18695594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global preventive policies. Strategies at European and worldwide level.
    Kotseva K
    Rev Esp Cardiol; 2008 Sep; 61(9):960-70. PubMed ID: 18775238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardiovascular risk factors. Insights from Framingham Heart Study].
    O'Donnell CJ; Elosua R
    Rev Esp Cardiol; 2008 Mar; 61(3):299-310. PubMed ID: 18361904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State consensus guideline for the prevention of cardiovascular disease in primary care settings.
    Smith CS; Harbrecht MG; Coronel SM; Krantz MJ
    Crit Pathw Cardiol; 2008 Jun; 7(2):122-5. PubMed ID: 18520529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Telemonitoring of cardiovascular diseases in Germany. Standing position and perspectives].
    Helms TM; Zugck C; Pelleter J; Ronneberger DL; Korb H
    Herz; 2007 Dec; 32(8):641-9. PubMed ID: 18060611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The influence of targeted intervention on the incidence of risk factors of cardiovascular diseases at medical staff].
    Sovová E; Nakládalová M; Kaletová M; Lukl J; Benusová I; Doupalová P
    Vnitr Lek; 2006 Jan; 52(1):21-5. PubMed ID: 16526194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology.
    Graham IM; Stewart M; Hertog MG;
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):839-45. PubMed ID: 17001227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychosocial and behavioral aspects of cardiovascular disease prevention in men and women.
    Orth-Gomér K
    Curr Opin Psychiatry; 2007 Mar; 20(2):147-51. PubMed ID: 17278913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging risk factors for cardiovascular disease: a review of the epidemiologic evidence for lipoprotein(a), homocysteine, and fibrinogen.
    Catena C; Cavarape A; Dotto L; Colussi G; Novehllo M; De Marchi S; Sechi LA
    Adv Clin Path; 2003 Jan; 7(1):3-11. PubMed ID: 19774732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.
    Sousa CS; Fonseca T; Clara JG
    Rev Port Cardiol; 2008 Apr; 27(4):513-27. PubMed ID: 18605070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.